ARCHIVES

XGEVA not Inferior to Zometa In 1,776-Patient Phase III Study

This article is from The Cancer Letter archive.

Vol. 34 No. 3 | March 25, 2011

Download PDF Visit The Full Archive

Related Articles

European regulators plan more rigorous rules for accelerated approval in cancer.

November 11, 2005

Caplan: NEJM Should Go “The Extra Moral Mile”

January 9, 2009

COG’s Peter Adamson Has A Conversation With The Cancer Letter

March 15, 2013

In Brief: Howley, Simone Lead Cancer Policy Board: AMA Campaign Fights Youth Smoking

November 22, 1996

NCI/NTP Studies Found EDB Carcinogenic, But Risk To Human Said Not Conclusive

March 23, 1984

Levine, Mendelsohn Win Landon Awards; Ullrich Wins Pezcoller.

February 29, 2008